Delivery Order SPE2DB20D1109-SPE2DB22FP38Q
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,496.68 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The award is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $2,076.20 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription eye medication, to support military and government healthcare programs. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc.,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The $82,820.34 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical valued at up to $999,999,999.00 through November 2026. This IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,558,152,346 units of RESTASIS 0.05% eye emulsion. The $8,122.89 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 held by Amerisourcebergen's parent company, Cencora, Inc., which runs through November 2026. This IDC serves as the primary vehicle for Cencora,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,083.53 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which enables the government to...
- This federal contract award, valued at $12,230.08, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract involves the delivery of RESTASIS 0.05% eye emulsion 60s, a pharmaceutical product used for ophthalmic treatment. The contract is a delivery order that is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
- The federal contract award summarized in the provided information was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,087.58, is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. This contract award appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $45,516.89 firm fixed-price contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract is not associated with a set-aside program and is an open competition award. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,958.72 Delivery Order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support...
- This federal contract award, valued at $3,080.28, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract is a firm fixed-price Delivery Order, with an ultimate completion date of October 17, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB22FP38QDelivery Order
This federal contract award is for a delivery order placed by the Defense Logistics Agency (DLA) with Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,843.23 firm fixed-price contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication used to treat dry eye disease. The contract award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Cencora, Inc. to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 6/7/22 |